17th Mentored Paper (Winter 2026)

Topics

MPI 17.1: What are the EEG biomarkers of craving of non-substances (internet, food, porn, actions)?

MPI 17.2: What are the EEG biomarkers of exercise therapy in psychiatric disease?

MPI 17.3: What are the EEG biomarkers of psychiatric disease concurrent with intellectual disability?

MPI 17.4: How does diet composition affect blood glucose control in individuals with Type 2 diabetes?

MPI 17.5: How can mobile health interventions improve medication adherence and diabetes screening rates in new immigrant populations with Type 2 diabetes?

MPI 17.6: How does inflammation impact recovery post trauma?

MPI 17.7: What is the role of immune cells in the pathophysiology post injury?

MPI 17.8: How do experiences of maternal health care differ between Indigenous and non-Indigenous women in Canada, and what are the implications for health outcomes and healthcare delivery?

MPI 17.9: How do eligibility criteria for public coverage of HIV PrEP differ across Canadian Provinces and what are the potential implications for health equity : a National Level Policy Scan?

MPI 17.10: What is the availability of sexual health services (screening and regular testing) across Canadian provinces and territories: A Scooping Review?

MPI 17.11: How do young adults (18-25) perceive and experience access to sexual health services and treatment at different healthcare settings, specifically comparing University Health Clinics to other available service locations: a qualitative study?

MPI 17.12: How do neuron-microglia interactions influence neuroinflammation in neurodevelopmental disorders?

MPI 17.13: How does exercise impact the health of our fat tissue?

MPI 17.14: Is exercise the best method for weight loss?

MPI 17.15: What is the relationship between our muscles and our fat issue during exercise?

MPI 17.16: How do dual GLP-1/GIP receptor agonists differ from GLP-1 agonists for diabetes management?

MPI 17.17: What role do platelets play in the progression of cardiometabolic disease?

MPI 17.18: How does inflammation impact recovery post trauma?"

MPI 17.19: How can methods of manufacturing or changes in materials being used for medicines or medical equipment during a pandemic help hospital reduce the shortage of medicines and keep administering essential treatments.

MPI 17.20: How do we use nanomaterials for biomedical applications or for the treatment of complex diseases, such as cancers being treated with gold nanoparticles, and nanomaterials used in pharmaceutical applications in drug delivery system.

MPI 17.21: How can we use lean six sigma philosophy in palliative care, and reduce wastage, and increase precision in the care for patients?

MPI 17.22: How do experiences of maternal health care differ between Indigenous and non-Indigenous women in Canada, and what are the implications for health outcomes and healthcare delivery?

MPI 17.23: How do nurse-family care programs address the needs and challenges faced by vulnerable mothers in Canada, and how effective are these programs in improving maternal and child health outcomes?